David A. Siegel Hille Vax, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Hille Vax, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 23,300 shares of HLVX stock, worth $45,202. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,300
Previous 16,100
44.72%
Holding current value
$45,202
Previous $232,000
82.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HLVX
# of Institutions
80Shares Held
36.8MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$20.6 Million1.01% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$9.54 Million0.74% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$4.06 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.8 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.65 Million0.06% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $64.8M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.